Premium
Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C
Author(s) -
Gutierrez J. A.,
Lawitz E. J.,
Poordad F.
Publication year - 2015
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12422
Subject(s) - ombitasvir , paritaprevir , dasabuvir , sofosbuvir , simeprevir , medicine , ledipasvir , tolerability , combination therapy , daclatasvir , clinical trial , ribavirin , hepatitis c , chronic hepatitis , virology , adverse effect , virus
Summary The treatment environment for chronic hepatitis C has undergone a revolution, particularly in genotype 1. Gone are interferon‐based therapy and its associated tolerability challenges, inadequate response rates and numerous baseline factors that affect response to therapy. New and emerging treatment regimens employ all‐oral combinations of direct‐acting antiviral agents, and results of clinical trials suggest that these regimens routinely achieve cure rates >90%, even in patients who failed prior interferon‐based triple therapy. In 2015, three all‐oral FDA ‐approved regiments will be available for genotype 1 (sofosbuvir /ledipasvir, sofosbuvir/simeprevir, and paritaprevir/r/ombitasvir/dasabuvir). Furthermore, new treatment combinations appear to be more tolerable and require shorter duration of therapy. We provide an overview of the classes of direct‐acting antiviral agents ( DAA s), the clinical factors affecting their integration into combination therapies and recent findings from trials of such combination therapies in patients with genotype 1 HCV infection.